NODDI-TRACT: Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery

Sponsor
GCS Ramsay Santé pour l'Enseignement et la Recherche (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05669326
Collaborator
(none)
12
1
1
12
1

Study Details

Study Description

Brief Summary

The objective of this study is to evaluate to what extent the capacity of the NODDI model can allow, in case of Malignant brain tumor patients with vasogenic edema, the elaboration of a reliable cerebral functional mapping in accordance with the data of direct electrical stimulation (DES) which is today the reference tool.

the patient's participation in this study implies an additional visit during which an MRI examination without injection of contrast medium will be performed, lasting approximately 40 minutes (including installation and de-installation).

Condition or Disease Intervention/Treatment Phase
  • Other: NODDI TRACT
N/A

Detailed Description

This is a single-center, prospective, open-label study of neurosurgical patients.

Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without injection of contrast product will be performed, lasting approximately 40 minutes (including installation and de-installation).

The operative time, surgical procedures and postoperative follow-up are not modified in this study

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: NODDI TRACT

Diffusion MRI (tractography) Tractography is performed on the basis of a diffusion MRI sequence which, after computer processing, will result in a map of the apparent diffusion coefficient and a diffusion tensor beam reconstruction (DTI tractography) performed with the Sisyphus software. Multi-shell diffusion MRI (NODDI-tract)

Other: NODDI TRACT
Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without contrast injection will be performed, lasting approximately 40 minutes (including installation and deinstallation). The operative time, surgical procedures and postoperative follow-up are not modified in this study.

Outcome Measures

Primary Outcome Measures

  1. Response to electrical stimulation [Hour 24]

    Response to electrical stimulation, which determines the presence or absence of an essential bundle, is the primary end point. The ability of the NODDI-tract method to reconstruct essential bundles in vasogenic edema will be assessed by estimating the correspondence between the response to intraoperative direct electrical stimulation (DES) and the presence of an MRI reconstructed bundle. Based on the response to electrical stimulation, the NODDI-tract data will be classified into one of four groups: True positive = response to stimulation and presence of an MRI beam True negative = no response to stimulation and no beam on MRI False positive = no response to stimulation and presence of a beam on MRI False-negative = response to stimulation and absence of beam in MRI. The distance between the reconstructed beam and the stimulation point (whether or not the stimulation was effective) will also be measured.

Secondary Outcome Measures

  1. Number of reconstructed fibers [Hour 24]

    Reconstructions obtained using the NODDI protocol or tractography will be compared on the total number of fibers reconstructed by both methods. The comparison will be made on the total number of reconstructed fibers and on the number of reconstructed fibers crossing the edema.

  2. Average distance to a reference atlas [Hour 24]

    The comparison is based on the evaluation of the average distance between the skeleton of the NODDI-tract reconstructed beams and that of the JHU tractography atlas [20]. The distance will be calculated by projecting the reconstructed skeleton onto the atlas skeleton, and as a function of the length traveled on the parameterized curve representing the skeleton. This function will be averaged over the entire length of the skeleton. An average distance of less than 1cm will be considered as a match criterion.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient 18 years of age or older,

  • Patient who has read and signed the consent form for participation in the study

  • Patient requiring surgery for a malignant brain tumor with vasogenic edema

  • Patient with an estimated life expectancy of more than 3 months.

Exclusion Criteria:
  • Patient under legal protection, guardianship or trusteeship

  • Patient not affiliated to the French social security system

  • Contraindication to MRI (patient with a pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, patient with hemostatic clips on intracerebral aneurysms or with orthopedic implants, claustrophobic patient)

  • Psychiatric history

  • Refusal to be informed of an abnormality detected during the MRI

  • Pregnant or breastfeeding woman

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinique de l'Union Saint-Jean France 31240

Sponsors and Collaborators

  • GCS Ramsay Santé pour l'Enseignement et la Recherche

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
GCS Ramsay Santé pour l'Enseignement et la Recherche
ClinicalTrials.gov Identifier:
NCT05669326
Other Study ID Numbers:
  • 2021-A02074-37
First Posted:
Dec 30, 2022
Last Update Posted:
Dec 30, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 30, 2022